VAY 736

Drug Profile

VAY 736

Alternative Names: NOV-5; VAY-736

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MorphoSys; Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MorphoSys; Novartis
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Neuropsychotherapeutics; Skin disorder therapies
  • Mechanism of Action B-cell activation factor receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 12 Jul 2017 Novartis Pharmaceuticals plans the phase II/III AMBER trial in Autoimmune hepatitis (NCT03217422; EudraCT2017-001555-32)
  • 27 Jun 2017 Phase-II clinical trials in Sjogren's syndrome in Germany, Japan, Spain, Portugal, Hungary, Austria (SC) (EudraCT2016-003292-22) (NCT02962895)
  • 27 Mar 2017 Novartis plans regulatory submissions for Sjoegren's syndrome in 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top